-
Dec 3, 2024 | 
shorturl.at | Kristin Sokol |Erica Sloan
In 2015, Marla Barkoff, MD, was a healthy mom and board-certified endocrinologist practicing at the University of Illinois Hospital in Chicago when a bunch of debilitating symptoms landed her on the opposite side of an exam room. It all started when she came down with strep throat. A prescription for penicillin knocked out the infection, no problem—but within a month, “I was unrecognizable,” she tells SELF.
-
Nov 29, 2024 | 
hcplive.com | Kristin Sokol |Vivian P Hernandez-Trujillo |Priya Bansal
OpinionPodcastNovember 29, 2024Author(s):, Patient education and shared decision-making enhance treatment alignment with patient values and preferences, improving therapy outcomes. Unmet needs in CSU management include more effective treatments and a deeper understanding of disease mechanisms. The field of CSU management is advancing with biologics and personalized medicine approaches, offering new therapeutic options.
-
Nov 22, 2024 | 
hcplive.com | Kristin Sokol |Vivian P Hernandez-Trujillo |Priya Bansal
OpinionPodcastNovember 22, 2024Author(s):, Biologics, especially monoclonal antibodies, provide targeted, personalized treatment options in CSU management, improving efficacy and safety profiles. BTK inhibitors offer a novel therapeutic approach by modulating B-cell receptor signaling, potentially benefiting patients unresponsive to conventional therapies. Future advancements in CSU management may focus on precision medicine to optimize biologics and BTK inhibitors, enhancing patient outcomes.
-
Nov 22, 2024 | 
hcplive.com | Kristin Sokol |Vivian P Hernandez-Trujillo |Priya Bansal
OpinionPodcastNovember 22, 2024Author(s):, Biologics for CSU face challenges including high costs, side effects, and the necessity for accurate patient selection to ensure treatment efficacy. BTK is a key player in mast cell degranulation, making it an ideal target for CSU treatment by potentially reducing histamine release. Targeting BTK offers a more specific treatment approach for CSU, addressing the condition's underlying pathophysiology.
-
Nov 15, 2024 | 
hcplive.com | Kristin Sokol |Vivian P Hernandez-Trujillo |Priya Bansal
OpinionPodcastNovember 15, 2024Author(s):, Second-generation H1 antihistamines may have limited efficacy and potential side effects at higher doses, necessitating careful consideration in therapy management. Increased antihistamine dosages are recommended for non-responders, but this approach has limitations, including potential side effects and diminishing returns.
-
Nov 15, 2024 | 
hcplive.com | Kristin Sokol |Vivian P Hernandez-Trujillo |Priya Bansal
OpinionPodcastNovember 15, 2024Author(s):, Treatment goals are shaped by disease severity, patient preferences, and clinical guidelines, ensuring personalized care. Antihistamines are the first-line treatment, with updosing considered for insufficient response by altering dosage or interval. Omalizumab is the second-line treatment, initiated at 300 mg every four weeks, followed by cyclosporine as the third-line option.
-
Nov 8, 2024 | 
consultantlive.com | Kristin Sokol |Vivian P Hernandez-Trujillo |Priya Bansal
Peer Exchange: Evolving Perspectives and Treatment Strategies in Chronic Spontaneous Urticaria - Episode 6Published on: , , , Panelists discuss the appropriate timing for general practitioners to refer patients with chronic spontaneous urticaria (CSU) to specialists, examining real-world referral patterns and the dynamics between dermatologists and allergists in managing the condition.
-
Nov 8, 2024 | 
hcplive.com | Kristin Sokol |Vivian P Hernandez-Trujillo |Priya Bansal
OpinionPodcastNovember 8, 2024Author(s):, Routine blood tests, such as ESR, CRP, IgG anti-TPO, and total IgE, are recommended for diagnosis. Biopsy is generally not required for diagnostic testing in this context. Disease severity is assessed using UAS7 and UCT, evaluating symptom frequency, intensity, and control.
-
Nov 1, 2024 | 
hcplive.com | Kristin Sokol |Vivian P Hernandez-Trujillo |Priya Bansal
OpinionPodcastNovember 1, 2024Author(s):, CSU diagnosis requires detailed patient history and symptom assessment, focusing on wheals, hives, and angioedema. The chronic and spontaneous nature of CSU complicates diagnosis due to symptom variability and lack of identifiable triggers. Exclusion of other potential causes is crucial, often necessitating laboratory tests to rule out underlying conditions.
-
Nov 1, 2024 | 
hcplive.com | Kristin Sokol |Vivian P Hernandez-Trujillo |Priya Bansal
OpinionPodcastNovember 1, 2024Author(s):, CSU pathogenesis involves complex mechanisms, including mast cell activation and degranulation, contributing to the condition's symptoms. Novel mechanisms of mast cell activation have been identified, enhancing understanding of CSU and revealing potential therapeutic targets. Bruton's tyrosine kinase (BTK) is a key mediator in mast cell degranulation and histamine release, offering a promising target for intervention.
